Search clinical trials for: Placebo to fluticasone/salmeterol

Total 1556 results

GlaxoSmithKline

Completed

Study Of Asthma In Patients Of African Descent

Asthma

United States
GlaxoSmithKline

Completed

ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the GSK Group of Companies.

Pulmonary Disease, Chronic Obstructive

United States, Canada
GlaxoSmithKline

Completed

A Study to Evaluate the 24 Hour Spirometric Effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate (FF)/25mcg Vilanterol (VI)) Compared With Salmeterol/Fluticasone Propionate Inhalation Powder (50mcg Salmeterol/500mcg Fluticasone Propionate (FP))

Pulmonary Disease, Chronic Obstructive

France, Germany, Spain, Russian Federation, Belgium, Ukraine, Philippines, Italy, Poland
Actavis Inc.
Teva Pharmaceuticals USA

Completed

Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With Asthma

Asthma

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler

Asthma

United States, Georgia, Hungary, Russian Federation, Ukraine
Novartis Pharmaceuticals

Withdrawn

A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD

Chronic Obstructive Pulmonary Disease

Germany, Austria
GlaxoSmithKline

Completed

Special Drug Use Investigation for ADOAIR DISKUS COPD (Salmeterol and Fluticasone)

Pulmonary Disease, Chronic Obstructive

Japan
GlaxoSmithKline

Completed

Influence Of Salmeterol Xinafoate/Fluticasone Propionate (50/500 µg BID) On The Course Of The Disease And Exacerbation Frequency In COPD Patients Gold Stage III And IV

Pulmonary Disease, Chronic Obstructive

Germany
GlaxoSmithKline

Completed

Validation of a New Shortness of Breath With Daily Activities Questionnaire in Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

United States
GlaxoSmithKline

Completed

Treatment Of Partial Reversible Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Netherlands
Research in Real-Life Ltd
Mundipharma Research Limited

Completed

Real-world Effectiveness of Combination Therapy in Asthma

Asthma

United Kingdom
GlaxoSmithKline

Completed

Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma

Asthma

United States, Canada, Russian Federation, Mexico, Australia, Ukraine
West-Ward Pharmaceutical

Completed

Clinical Endpoint Bioequivalence Study of Fluticasone Propionate & Salmeterol Xinafoate (100μg/50μg)

Asthma

United States
Università degli Studi di Ferrara
GlaxoSmithKline

Completed

Effects of Inhaled Corticosteroids on Sputum Bacterial Load in COPD

Chronic Obstructive Pulmonary Disease

Italy
Imperial College London
European Research Council

Recruiting

Mechanisms of Adverse Effects of Long-Acting Beta-Agonists in Asthma (MAELABA)

Asthma

United Kingdom
Orion Corporation, Orion Pharma

Completed

Comparing Salmeterol/Fluticasone Easyhaler and Seretide Diskus (SAIMI)

Asthma

Finland
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Salmeterol Xinafoate and Fluticasone Propinate Powder for Inhalation for Asthma

Asthma

China
GlaxoSmithKline

Completed

Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol)

Respiratory Disorders
Northwestern University
GlaxoSmithKline

Withdrawn

The Impact of Salmeterol-Fluticasone on Sleep in Patients With COPD (AQuOS-COPD)

Chronic Obstructive Pulmonary Disease | Sleep Disorders

United States
GlaxoSmithKline

Completed

Study Of Allergic Rhinitis In Patients Who Also Have Asthma

Asthma

United States, Estonia, Canada, Poland
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States
University Medical Center Groningen

Unknown

Symptom-driven Maintenance and Reliever Treatment to Prevent Exacerbations in COPD

COPD

Netherlands
The Korean Academy of Tuberculosis and Respiratory...
GlaxoSmithKline

Completed

Clinical Outcomes of Tiotropium Plus Fluticasone Propionate/Salmeterol Compared With Tiotropium for Chronic Obstructive Pulmonary Disease (COPD) in Korea

Chronic Obstructive Pulmonary Disease

Korea, Republic of
Allergy & Asthma Medical Group & Research Center

Completed

Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 mcg BID

Asthma | Candidiasis, Oral | Voice Disorders

United States
GlaxoSmithKline

Completed

A Comparative Study To Determine If Motivating Asthma Education (Compliance Enhancement) Has An Effect On Asthma Control

Asthma

Denmark, Switzerland
Eurofarma Laboratorios S.A.

Completed

A Non- Inferiority Comparative Study Between Seretide® and Salmeterol/Fluticasone Eurofarma in Patients With Asthma (CAINAS SF)

Asthma

Brazil
Ache Laboratorios Farmaceuticos S.A.

Withdrawn

Efficacy and Safety Study of Formoterol/Fluticasone and Salmeterol/Fluticasone in Patients With Moderate-to-severe COPD

Chronic Obstructive Pulmonary Disease | COPD
Novartis

Completed

Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Using Salmeterol as Active Control

Chronic Obstructive Pulmonary Disease (COPD)

Russian Federation, Germany, Denmark, Italy, Canada, Czech Republic, Hungary, India, Slovakia, France, Colombia, Finland, Taiwan, Iceland, Peru
Novartis

Completed

Study of Indacaterol Dosed in the Evening in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Germany, Spain, France
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma

Asthma

United States
Cipla Ltd.

Completed

BE Study of Fluticasone Propionate/Salmeterol Inhalation Powder in Asthma Patients

Bronchial Asthma

United States
Novartis Pharmaceuticals

Completed

Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma

Asthma

Germany, Spain, United States, Turkey, Canada, Hungary, Slovakia, Italy, Argentina, Czech Republic, France, Peru
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD) (INSIST)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Germany, Spain, Turkey, Hungary, Czech Republic, India, Slovakia
GlaxoSmithKline

Completed

Special Drug Use Investigation for ADOAIR Metered-dose Inhaler (Pediatric)

Asthma
Novartis Pharmaceuticals

Withdrawn

A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD

Chronic Obstructive Pulmonary Disease

Colombia, India, Belgium, Argentina, Czech Republic
GlaxoSmithKline

Completed

A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With Asthma

Asthma

United States, Russian Federation, Canada, Germany, Peru, Australia, Mexico, Chile, Costa Rica, Spain, Poland, Lithuania, Latvia
GlaxoSmithKline

Completed

Study Of Airway Physiology In Adults. SERETIDE DISKUS® Inhaler and FLIXOTIDE® Inhaler Are Trademarks of GSK Croup of Companies.

Asthma

United Kingdom
GlaxoSmithKline

Completed

Study In Airway Physiology In Children SERETIDE DISKUS ® Inhlaer and FLIXOTIDE® Inhaler Are Trademarks of GSK Group of Companies.

Asthma

United Kingdom, New Zealand
Kindeva Drug Delivery

Completed

Single Blind Cross-over Dose Response Study in Subjects of Two Inhalers of Salmeterol and Fluticasone Propionate

Healthy

United Kingdom
Università degli Studi di Brescia

Completed

Effects on Small Airways of Two Long-term Extrafine Treatments in Asthma (FORTINO)

Bronchial Asthma
GlaxoSmithKline

Completed

A 3 Way Cross-over Study Evaluating the Effects of ADOAIR Twice Daily Plus Tiotropium Bromide Once Daily Compared With the Individual Treatments of Japanese Subjects (SCO116572)

Pulmonary Disease, Chronic Obstructive

Japan
National Jewish Health
GlaxoSmithKline

Terminated

Evaluating Genes in Sputum to Measure Drug Response in COPD

Emphysema | Chronic Obstructive Pulmonary Disease (COPD) | Chronic Bronchitis

United States
University of Rostock
GlaxoSmithKline

Completed

Effect of Salmeterol on Brain-Derived Neurotrophic Factor (BDNF) Concentrations in Asthma

Allergic Asthma

Germany
University of Colorado, Denver
United States Department of Defense

Recruiting

Advair HFA in Healthy and HAPE Predisposed Subjects (SWIFTARC)

Altitude Edema

United States
GlaxoSmithKline

Terminated

ADVAIR DISKUS® (Fluticasone Propionate/Salmeterol) Inhaler Versus SEREVENT DISKUS® (Salmeterol) Inhlaer On Inflammatory Cells And Markers In Chronic Obstructive Pulmonary Disease. ADVAIR DISKUS® and SEREVENT DISKUS® Inhalers Are Trademarks of the GSK Group of Companies.

Pulmonary Disease, Chronic Obstructive

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Study to Determine the Pharmacokinetics and Tolerability of Fluticasone Propionate MDPI and Fluticasone Propionate/Salmeterol MDPI Compared to High Strength FLOVENT® DISKUS® and ADVAIR® DISKUS® in Patients With Persistent Asthma 12 Years of Age and Older

Asthma

United States
Mundipharma (China) Pharmaceutical Co. Ltd

Unknown

Efficacy of FLUTIFORM ® vs Seretide® in Moderate to Severe Persistent Asthma in Subjects Aged ≥12 Years

Asthma

China
GlaxoSmithKline

Completed

Study Of Patients With Allergic Rhinitis And Asthma

Asthma

United States
Neutec Ar-Ge San ve Tic A.Ş

Terminated

Salmeterol/Fluticasone 50/500 mcg Inhalation Powder Via Capsair vs Seretide Diskus 500 mcg Inhalation Powder in Patients With COPD (COPD)

COPD

Turkey
Organon and Co

Completed

Study of Mometasone Furoate/Formoterol Combination and Fluticasone/Salmeterol in Persistent Asthmatics Previously Treated With Inhaled Glucocorticosteroids (P04139)

Asthma

3

Subscribe